Senseonics Holdings (SENS) AI Stock Analysis

• Market Cap: $245.97M
• Dividend Yield: N/A
• Average Volume (3M): 545.74K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.67
• Revenue Growth: 31.94%
• EPS Growth: 36.59%
• Country: US
• Employees: 117
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.40
• Shares Outstanding: 40,858,460
• 10 Day Avg. Volume: 458,698
• 30 Day Avg. Volume: 545,739
• PEG Ratio: -0.31
• Price to Book (P/B): -19.91
• Price to Sales (P/S): 14.67
• P/FCF Ratio: -5.26
• Enterprise Value/Market Cap: 1.31
• Enterprise Value/Revenue: 10.40
• Enterprise Value/Gross Profit: 24.99
• Enterprise Value/Ebitda: -5.80
• 1Y Price Target: $15.75
• Price Target Upside: 160.76% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 7
• EPS Forecast (FY): -1.56
• Revenue Forecast (FY): $35.29M

• Rating: 45 Neutral
• Price Target: $6.50 ▲(7.62% Upside)

Senseonics Holdings faces significant financial challenges, with high leverage and negative profitability metrics being the most impactful risks. Despite positive revenue growth and successful marketing strategies, the stock's bearish technical indicators and poor valuation metrics weigh heavily on its overall score.

Positive Factors

Revenue Growth

The significant revenue growth indicates strong market demand and successful product adoption, which can lead to improved financial stability and market position over time.

Direct-to-Consumer Strategy

The effective DTC strategy enhances brand visibility and patient acquisition, potentially leading to sustained revenue growth and market expansion.

Gross Margin Improvements

Improving gross margins reflect better cost management and pricing strategies, which can enhance profitability and financial health in the long term.

Negative Factors

High Leverage

High leverage poses financial risks, limiting the company's ability to invest in growth opportunities and making it vulnerable to economic downturns.

Ongoing Financial Losses

Continued financial losses indicate challenges in achieving profitability, which can hinder long-term financial sustainability and investor confidence.

Cash Flow Challenges

Cash flow challenges can restrict operational flexibility and limit the company's ability to fund strategic initiatives or respond to market changes.

Senseonics Holdings Business Overview & Revenue Model

Company Description

Senseonics Holdings, Inc., a medical technology company, develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes in the United States, Europe, the Middle East, and Africa. The company's products include Eversense and Eversense XL, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management for a period of up to six months. It serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. The company has a collaboration agreement with the University Hospitals Accountable Care Organization. Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.

How the Company Makes Money

Senseonics generates revenue primarily through the sale of its Eversense CGM systems, which include the implantable sensors, the associated applicators, and the mobile app. The company earns revenue from both product sales and recurring income from sensor replacements, as the sensors need to be replaced periodically. Key revenue streams include direct sales to healthcare providers, distribution agreements, and partnerships with diabetes care organizations. Additionally, Senseonics may benefit from strategic collaborations and agreements with larger healthcare firms, which can enhance market access and increase product adoption, further contributing to its earnings.

Senseonics Holdings Financial Statement Overview

Summary

Senseonics Holdings is experiencing revenue growth but faces significant challenges in profitability and financial stability. High leverage and negative profitability metrics pose risks, while cash flow management remains a concern. The company needs to improve operational efficiency and reduce debt to enhance financial health.

Income Statement

Senseonics Holdings has shown a positive revenue growth rate of 14.13% TTM, indicating potential for future growth. However, the company is struggling with profitability, as evidenced by negative net profit margins and EBIT margins. The gross profit margin has improved over the years but remains relatively low, reflecting challenges in cost management and pricing strategy.

Balance Sheet

The balance sheet reveals a high debt-to-equity ratio of 2.89 TTM, indicating significant leverage and potential financial risk. The return on equity is negative, suggesting inefficiencies in generating returns from shareholder investments. The equity ratio is low, highlighting a reliance on debt financing.

Cash Flow

Cash flow analysis shows a negative free cash flow growth rate and a negative operating cash flow to net income ratio, indicating cash flow challenges. However, the free cash flow to net income ratio is slightly above 1, suggesting that the company is managing to convert net income into free cash flow effectively.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	30.95M	22.47M	22.39M	16.39M	13.68M	4.95M
Gross Profit	12.88M	533.00K	3.09M	2.73M	-811.00K	-17.37M
EBITDA	-55.51M	-68.70M	-48.01M	161.81M	-284.51M	-157.86M
Net Income	-64.74M	-78.62M	-60.39M	142.12M	-302.47M	-175.17M
Balance Sheet
Total Assets	139.92M	100.44M	138.22M	177.67M	198.93M	35.92M
Cash, Cash Equivalents and Short-Term Investments	111.27M	74.60M	109.46M	144.01M	129.91M	18.00M
Total Debt	41.16M	61.05M	47.78M	75.38M	64.21M	62.70M
Total Liabilities	61.76M	116.99M	64.77M	180.25M	384.46M	180.00M
Stockholders Equity	78.17M	-16.55M	73.45M	-2.58M	-185.53M	-144.08M
Cash Flow
Free Cash Flow	-56.17M	-62.70M	-70.51M	-66.62M	-56.29M	-67.60M
Operating Cash Flow	-55.41M	-60.47M	-70.16M	-66.31M	-56.08M	-67.42M
Investing Cash Flow	-28.40M	32.84M	89.71M	26.88M	-148.75M	-181.00K
Financing Cash Flow	91.16M	26.83M	20.37M	41.76M	220.08M	-10.13M

Senseonics Holdings Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 6.04
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SENS, the sentiment is Negative. The current price of 6.04 is below the 20-day moving average (MA) of 6.22, below the 50-day MA of 7.64, and below the 200-day MA of 10.85, indicating a bearish trend. The MACD of -0.55 indicates Negative momentum. The RSI at 42.49 is Neutral, neither overbought nor oversold. The STOCH value of 43.96 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SENS.

Senseonics Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PODD	74 Outperform	$23.13B	95.42	19.68%	―	27.12%	-41.72%
DXCM	69 Neutral	$24.06B	34.34	30.63%	―	14.21%	5.66%
LIVN	63 Neutral	$3.49B	―	-17.63%	―	8.97%	-1024.86%
TNDM	60 Neutral	$1.41B	―	-109.73%	―	17.87%	-57.03%
XTNT	60 Neutral	$88.19M	61.67	3.64%	―	16.88%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SENS	45 Neutral	$245.97M	―	-129.29%	―	31.94%	36.59%

Senseonics Holdings Corporate Events

Senseonics’ Earnings Call Highlights Growth Amid Challenges

Senseonics Holdings Inc. recently held its earnings call, revealing a generally positive sentiment driven by significant revenue growth and successful marketing strategies. The company reported record new patient starts and highlighted its direct-to-consumer approach as a key factor in its positive outlook. However, ongoing financial losses and anticipated inventory challenges during the transition from Ascensia were noted as areas of concern.

Senseonics Reports Strong Revenue Growth and Strategic Moves

Senseonics Holdings, Inc. is a medical technology company specializing in the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for individuals with diabetes. The company is known for its innovative Eversense CGM systems, which offer extended wear durations compared to traditional glucose monitors.

Senseonics Announces Reverse Stock Split Effective October 17

On October 16, 2025, Senseonics Holdings, Inc. announced a one-for-twenty reverse stock split of its common stock, effective October 17, 2025. This adjustment will proportionately decrease the number of authorized shares and affect stock options, restricted stock units, and warrants, with trading on a split-adjusted basis beginning October 20, 2025, under the ticker symbol ‘SENS’.

The most recent analyst rating on (SENS) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Senseonics Holdings stock, see the SENS Stock Forecast page.

Senseonics Approves Reverse Stock Split Proposal

On September 29, 2025, Senseonics Holdings, Inc. held a special meeting where stockholders approved a proposal for a reverse stock split of the company’s common stock, with a reduction in the authorized number of shares, in a range of 1-for-10 to 1-for-20. This decision, which can be enacted any time before September 29, 2026, is intended to potentially enhance the company’s stock market positioning and operational flexibility.

The most recent analyst rating on (SENS) stock is a Buy with a $1.25 price target. To see the full list of analyst forecasts on Senseonics Holdings stock, see the SENS Stock Forecast page.

Senseonics Expands Debt Facility with Hercules Capital

On September 3, 2025, Senseonics Holdings entered into an Amended Loan Agreement with Hercules Capital, expanding their non-dilutive debt facility to $100 million to fund their commercial organization. This agreement includes an initial term loan of $35 million and additional tranches, with the loans maturing on September 3, 2029. Concurrently, Senseonics signed a Memorandum of Understanding with Ascensia Diabetes Care to transition the commercialization and distribution of Eversense 365 back to Senseonics by January 1, 2026. This strategic move aims to unify the Eversense business under Senseonics, potentially accelerating growth and improving operational efficiency. Brian Hansen, Ascensia’s President of CGM, will join Senseonics as Chief Commercial Officer to lead these efforts.

The most recent analyst rating on (SENS) stock is a Buy with a $1.50 price target. To see the full list of analyst forecasts on Senseonics Holdings stock, see the SENS Stock Forecast page.